Pfizer and BioNTech Report Results of BNT162b2 to Prevent COVID-19
Shots:
- The P-III study evaluating BNT162b2 (COVID-19 Vaccine) vs PBO in >44-000 participants age ≥16 yrs with 927 confirmed symptomatic cases of COVID-19
- The results demonstrated that BNT162b2 is 91.3% effective against COVID-19- follow-up time of at least 6 mos after the 2nd dose- 100% effective in preventing severe disease by CDC- 95.3% effective against severe COVID-19 by US FDA- effective against B.1.351 variant- safe and tolerable
- The companies plan to share the results with worldwide regulatory agencies
Ref: Pfizer | Image: Bloomberg Quint
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com